BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ:SLXN), a micro-cap biotech firm with a market capitalization of $5.92 million focusing on RNA interference therapies for KRAS-driven cancers, announced a strategic collaboration with Catalent for the development and manufacturing of its siRNA candidate, SIL204. This partnership aims to optimize SIL204’s formulations for systemic and intratumoral delivery, targeting primary tumors and metastases in KRAS-driven cancers.
The collaboration leverages Catalent’s expertise in advanced delivery technologies at its Limoges facility, which specializes in complex injectable formulations. This move is a progression from Silexion’s reported preclinical data showing SIL204’s efficacy in reducing tumor growth and metastatic spread in pancreatic cancer models.
Silexion’s Chairman and CEO, Ilan Hadar, stated that this partnership marks a significant step in the SIL204 development program, following promising preclinical results. He expressed anticipation for the collaboration’s contribution to the goal of initiating human clinical trials in the first half of 2026. According to InvestingPro data, analysts have set a target price of $5 for SLXN, significantly above its current trading price of $0.70, though investors should note the company’s weak financial health score of 0.59.
Silexion plans to conduct further toxicology and pharmacodynamic studies throughout 2025, with potential regulatory submissions to the Israel Ministry of Health in the second half of 2025 and to the European Union in the first half of 2026. Catalent’s sustained-release technologies are expected to enhance SIL204’s stability, bioavailability, and delivery precision.
The company’s first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion continues to focus on improving outcomes for patients with difficult-to-treat cancers by developing therapies targeting a broad spectrum of KRAS mutations. InvestingPro analysis reveals the stock has experienced significant volatility, with a 99.3% decline over the past year. Subscribers can access 7 additional ProTips and comprehensive financial metrics to better evaluate the company’s potential.
This press release contains forward-looking statements regarding Silexion’s business strategy, collaboration with Catalent, and plans for future studies and regulatory submissions. These statements involve risks, uncertainties, and assumptions, and actual results may differ materially from those projected. The company’s next earnings report is expected on June 13, 2025, which could provide additional insights into the development program’s progress.
The information is based on a press release statement from Silexion Therapeutics Corp.
In other recent news, Silexion Therapeutics Corp. has announced significant preclinical results for its drug candidate SIL-204, targeting KRAS-driven cancers. The company revealed that systemic administration of SIL-204 substantially reduced tumor growth in pancreatic cancer models, with some tumors exhibiting complete necrosis. Additionally, Silexion has expanded its development strategy for SIL-204, planning further studies to assess its impact on metastatic progression. The firm anticipates regulatory submissions in 2025 and aims to initiate human trials in 2026. In financial developments, Silexion reached an agreement with EarlyBirdCapital to retire a convertible promissory note. The deal involved a $400,000 cash payment and the issuance of 277,777 ordinary shares. This strategic move is part of Silexion’s financial management efforts. These recent developments highlight Silexion’s ongoing commitment to advancing cancer therapies and managing its financial obligations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.